AOP 208
Alternative Names: AOP-208; LB-208Latest Information Update: 08 Oct 2024
At a glance
- Originator Leukos Biotech
- Developer AOP Orphan Pharmaceuticals AG; Leukos Biotech
- Class Antineoplastics
- Mechanism of Action Serotonin 1B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
- Preclinical Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 01 Oct 2024 AOP Orphan Pharmaceuticals in-licenses AOP 208 from Leukos Biotech
- 01 Oct 2024 Phase-I clinical trials in Lymphoma, Solid tumours (PO)
- 22 Jan 2024 AOP 208 is available for licensing as of 22 Jan 2024. https://www.aop-health.com/global_en/partners/ (AOP Orphan Pharmaceuticals pipeline, January 2024)